首页> 外文期刊>ACS applied materials & interfaces >Liposomes Combined an Integrin alpha(v)beta(3)-Specific Vector with pH-Responsible Cell-Penetrating Property for Highly Effective Antiglioma Therapy through the Blood-Brain Barrier
【24h】

Liposomes Combined an Integrin alpha(v)beta(3)-Specific Vector with pH-Responsible Cell-Penetrating Property for Highly Effective Antiglioma Therapy through the Blood-Brain Barrier

机译:脂质体结合整合素α(v)beta(3)特定载体与pH负责的细胞穿透性质,通过血脑屏障进行高效抗神经胶质瘤治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Glioma, one of the most common aggressive malignancies, has the highest mortality in the present world. Delivery of nanocarriers from the systemic circulation to the glioma sites would encounter multiple physiological and biological barriers, such as blood brain barrier (BBB) and the poor penetration of nanocarriers into the tumor. To circumvent these hurdles, the paclitaxel-loaded liposomes were developed by conjugating with a TR peptide (PTX-TR-Lip), integrin alpha(v)beta(3)-specific vector with pH-responsible cell-penetrating property, for transporting drug across the BBB and then delivering into glioma. Surface plasmon resonance (SPR) studies confirmed the very high affinity of TR-Lip and integrin alpha(v)beta(3). In vitro results showed that TR-Lip exhibited strong transport ability across BBB, killed glioma cells and brain cancer stem cells (CSCs), and destroyed the vasculogenic mimicry (VM) channels. In vivo results demonstrated that TR-Lip could better target glioma, and eliminated brain CSCs and the VM channels in tumor tissues. The median survival time of tumor-bearing mice after administering PTX-TR-Lip (45 days) was significantly longer than that after giving free PTX (25.5 days, p < 0.001) or other controls. In conclusion, PTX-TR-Lip would improve the therapeutic efficacy of brain glioma in vitro and in vivo.
机译:胶质瘤是最常见的侵袭性恶性肿瘤之一,目前死亡率最高。纳米载体从全身循环传递到神经胶质瘤部位会遇到多种生理和生物学障碍,例如血脑屏障(BBB)和纳米载体向肿瘤的渗透性差。为了克服这些障碍,通过与TR肽(PTX-TR-Lip),整合素α(v)beta(3)特异性载体(具有pH负责的细胞穿透特性)结合,开发了紫杉醇负载脂质体,用于转运药物穿过血脑屏障,然后进入神经胶质瘤。表面等离子体共振(SPR)研究证实了TR-Lip和整联蛋白alpha(v)beta(3)的非常高的亲和力。体外结果显示,TR-Lip跨BBB表现出强大的转运能力,杀死了神经胶质瘤细胞和脑癌干细胞(CSC),并破坏了血管生成模拟物(VM)通道。体内结果表明,TR-Lip可以更好地靶向神经胶质瘤,并消除肿瘤组织中的脑CSC和VM通道。给予PTX-TR-Lip(45天)后的荷瘤小鼠的中位生存时间明显比给予游离PTX(25.5天,p <0.001)或其他对照后更长。总之,PTX-TR-Lip可提高体内外脑胶质瘤的治疗效果。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号